What Covalon Technologies does

Covalon Technologies Ltd. is a Canadian medical technology company founded in 2004 and dual-listed on the TSX Venture Exchange (TSXV:COV) and OTCQX (CVALF), headquartered in Mississauga, Ontario with a U.S. commercial office in Miami, Florida. The company researches, develops, and commercializes wound care dressings, vascular access dressings, and surgical consumables centered on a proprietary soft-silicone adhesive platform combined with dual-antimicrobial (chlorhexidine and silver) protection. Its technology stack includes the CovaCoat photochemical 'grafting from' surface modification process, the VALGuard line-to-line vascular access barrier with quick-release technology, and the ColActive PLUS collagen-EDTA-alginate-CMC wound dressing platform that inhibits matrix metalloproteinases to support chronic wound healing.

Covalon sells its products to acute care hospitals, integrated delivery networks (IDNs), wound care clinics, and vulnerable patient populations (neonatal, pediatric, oncology, sensitive skin) in North America. Its go-to-market combines enterprise field sales targeting large hospital systems and IDNs, GPO distribution via a Vizient Innovative Technology contract secured through strategic partner HARTMANN USA, a recruited distributor network, and direct e-commerce via its website. Revenue is generated entirely through hardware product sales (no subscription or service streams), with dressings priced $80–$275 per box of 25 units. The company emphasizes clinical validation, key opinion leader engagement (notably vascular access expert Dr. Nancy Moureau), and peer-reviewed evidence, with strong presence at industry conferences (INS, APIC, AVA, SAWC).

Financially, Covalon reported FY2025 revenue of $32.8 million (5% YoY growth, third consecutive year of growth), Q2 FY2026 revenue of $8.7 million (15% YoY growth), Q2 FY2026 gross margin of 61.5%, and net income of $1.1 million (up 155% YoY). The company holds $16.6 million in cash with zero bank debt as of March 31, 2026, and paid its first-ever special cash dividend in November 2025 reflecting six consecutive quarters of profitability. Customers include 8 of the top 10 U.S. children's hospitals and marquee accounts such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Texas Children's Hospital.

Name

Covalon Technologies

Legal name

Covalon Technologies Ltd.

Website

https://covalon.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Covalon Technologies is a Canadian medical technology company that develops and commercializes proprietary silicone-based wound care dressings, dual-antimicrobial vascular access dressings, and collagen wound dressings sold to hospitals, integrated delivery networks, and wound care clinics across North America.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Care & Ulcer Management (HLAKACAN)

akta.pro secondary industry

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

Keywords

• Wound care dressings
• Vascular access devices
• Infection prevention products
• Antimicrobial silicone dressings
• Medical device coatings

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical Device Product Sales: Sale of proprietary wound care dressings, vascular access products, and surgical consumables to hospitals, healthcare systems, and clinics. Revenue is generated through direct hospital purchasing, group purchasing organizations (Vizient), distributor agreements, and e-commerce channels. The company derives all revenue from product sales with no subscription or service revenue streams.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Covalon Technologies researches, develops, manufactures, and commercializes proprietary medical devices for wound care and infection prevention. Its product portfolio includes soft silicone IV dressings (CovaClear IV, IV Clear), vascular access line connection barriers (VALGuard), post-operative dressings (SurgiClear), and advanced collagen-based wound dressings (ColActive PLUS, ColActive PLUS Ag, and the CovaWound family). The underlying platform technology is CovaCoat, a proprietary photochemical surface modification process used to create antimicrobial silicone coatings for medical devices.

Product overview

Covalon Technologies is a medical technology company that develops and sells wound care and infection prevention products. The company operates as a single-brand portfolio with multiple product lines organized into solution categories. The core product portfolio includes: (1) Vascular Access Technologies featuring CovaClear IV (antimicrobial-free silicone IV dressing), IV Clear (dual-antimicrobial silicone dressing with chlorhexidine and silver), and VALGuard (line-to-line connection barrier); (2) Advanced Wound Care featuring ColActive PLUS collagen dressings with and without silver antimicrobial; and (3) a broader wound care sub-brand (CovaWound) including alginate, alginate Ag, foam, and hydrocolloid dressings. The company also offers CovaCoat, a proprietary dual antimicrobial silicone adhesive technology platform for medical device coatings. The products are united by Covalon's core technology of gentle silicone adhesives and dual antimicrobial protection (chlorhexidine and silver), with a focus on patient comfort and infection prevention.

Differentiator

Problem solved

Functional benefit

Brands

• ColActive PLUS: Advanced wound dressing brand including ColActive PLUS and ColActive PLUS Ag versions with collagen, EDTA, alginate, and CMC formulation for chronic stalled wounds.
• CovaClear
• IV Clear
• SurgiClear
• VALGuard
• CovaCoat
• CovaWound

Products and services

• CovaClear® IV A clear soft silicone adhesive IV dressing that protects IV insertion sites and primary dressings from external contaminants. Free from antimicrobials, designed for sensitive-skin patients including neonates and pediatric populations, and for those with chlorhexidine or acrylic adhesive allergies.
• IV Clear® The world's only dual-antimicrobial (chlorhexidine and silver) clear soft silicone IV securement dressing. Provides antimicrobial protection throughout the entire dressing surface area and kills on average 99.99% of microorganisms commonly associated with catheter-related bloodstream infections (CRBSI). Requires a valid prescription to purchase.
• VALGuard® The only vascular access line-to-line connection barrier with a quick-release strip for immediate access to catheter hubs. Transparent design allows continuous monitoring of hubs and connections while providing a barrier against gross contamination from body fluids, stool, urine, and secretions.
• SurgiClear®

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• HARTMANN USAcoreChannel Partner/ Reseller/ Distributor · 25 February 2026Strategic partner HARTMANN USA secured an Innovative Technology contract through Vizient (the largest group purchasing organization in the U.S.) for bundled collagen matrix dressings. This GPO contract provides Covalon access to Vizient member hospitals and health systems across the United States, significantly expanding market reach.
• Association for Vascular Access (AVA)coreStrategic or Co-development Partner · 19 February 2026Covalon partnered with AVA to co-host a Continuing Education webinar on IV line contamination and CABSI risk prevention, featuring vascular access expert Dr. Nancy Moureau. The webinar titled 'What Are We Missing? Closing an Overlooked Gap in Infection Prevention' was delivered on February 24, 2026. The partnership leverages AVA's professional network for clinician education and establishes Covalon as an education leader in vascular access.
• Dr. Nancy MoureaucoreStrategic or Co-development Partner · 19 February 2026Vascular access expert Dr. Nancy Moureau partnered with Covalon and AVA for a CE webinar on IV contamination and CABSI risk. She also delivered a podium presentation at the INS 2026 Annual Meeting on gaps in protection against gross contamination of IV access points. Dr. Moureau's KOL status is central to Covalon's clinical validation and education strategy.
• DEBRA CanadaminorOthersCovalon partners with DEBRA Canada, a voluntary non-profit supporting families affected by Epidermolysis Bullosa (EB), through product donations. DEBRA has been able to help many patients with EB through Covalon product donations, supporting compassionate care for patients with severe skin fragility.
• dEBra of AmericaminorOthersCovalon supports dEBra of America through product donations and company-wide initiatives to help patients with Epidermolysis Bullosa. dEBra's only securement dressing of choice is Covalon's IV Clear soft silicone dual antimicrobial dressing, demonstrating clinical preference for Covalon's gentle, infection-prevention products in a highly sensitive patient population.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Solventum (formerly 3M Health Care): Directly competing medical dressings, securement devices, and infection-prevention products across Covalon's vascular access and wound care lines. Solventum operates as a large diversified medical supplies incumbent, while Covalon differentiates on its dual-antimicrobial silicone and VALGuard line-guard niche.
• Becton, Dickinson and Company (BD): Major manufacturer of vascular access catheters, IV dressings, and insertion-site care products through its BD Medical segment. BD competes directly in PICC/CVC dressing securement and CRBSI-prevention adjacencies where Covalon's IV Clear and VALGuard operate.
• Cardinal Health (Medical segment): Major med-surg distributor with its own vascular access and wound care private-label offerings competing in the same hospital procurement channels as Covalon. Relevant as both a distributor competitor and broad incumbent in the hospital channel Covalon sells into.
• 3M (legacy Health Care) / KCI Medical: Through KCI (acquired by Solventum/3M), competes in advanced wound care with V.A.C. negative pressure wound therapy and foam dressings. Comparable chronic wound care portfolio to Covalon's ColActive PLUS and CovaWound lines targeting similar hospital wound clinics.

Direct peers

• Smith+Nephew: Global advanced wound care specialist offering collagen, alginate, foam, hydrocolloid, and antimicrobial dressings (e.g., PICO, ALLEVYN, INTRASITE). Direct overlap with Covalon's ColActive PLUS, CovaWound Alginate/Foam/Hydrocolloid, and silver-antimicrobial portfolio for chronic wound management.
• Convatec: Specialist in advanced wound care, ostomy, and continence care with AQUACEL and other collagen-based dressing platforms. Highly comparable to Covalon's advanced wound care business and its focus on diabetic foot ulcers, venous, and pressure ulcers.
• Mölnlycke Health Care: Specialist in advanced wound care (Mepilex, Mepitel) and surgical solutions including antimicrobial and silicone-based dressings. Comparable to Covalon's silicone-adhesive wound care platform and post-operative surgical dressings (SurgiClear).
• Coloplast: Wound and skin care division (Biatain, Purilon) competes with Covalon's advanced wound care portfolio, including foam, hydrocolloid, and antimicrobial dressings for chronic wounds. Comparable product categories and similar hospital/specialty channel focus.
• Hartmann Group (PAUL HARTMANN): Strategic distribution partner to Covalon (HARTMANN USA holds the Vizient GPO contract for Covalon collagen dressings) and a direct wound care/dressing competitor with product lines covering advanced wound management and infection prevention. Two-sided comparator as both partner and peer competitor.
• ICU Medical: Specialist in IV therapy, vascular access, and critical-care medical connectors, including needlefree connectors and IV accessories that intersect with Covalon's VALGuard line-to-line barrier and IV dressing products. Directly comparable vascular access infection-prevention portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/covalon
• Facebookfacebook.com/iv-clear-1667749943498987
• LinkedInlinkedin.com/company/covalon-technologies-ltd
• Instagraminstagram.com/covalon/?hl=en
• Xx.com/covalon

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Covalon Technologies